Incorporating the recently amassed clinical trial evidence-base of SGLT2 inhibitors on CV and renal outcomes, the treatment algorithm proposes an initial distinction of glucose-lowering medication based on clinical characteristics and the presence or absence of co-morbidities such as atherosclerotic CVD, HF or CKD. Here, SLC5A2 is linked to chronic kidney disease.